Photodynamic therapy for Barrett's esophagus: Does light still have a role?

Kenneth K. Wang, L. Lutzke, L. Borkenhagen, W. Westra, M. W.K. Song, G. Prasad, N. S. Buttar

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Photodynamic therapy was the first treatment to have been shown to significantly decrease high-grade dysplasia and cancer in patients with Barrett's esophagus. However, its use has been limited, primarily because of the side effects, which include esophageal strictures, cutaneous photosensitivity, chest pain, and nausea and vomiting [1]. The tolerability aspects of photodynamic therapy, as well as the dosimetry, though, can be improved with existing technologies to further develop this therapy into truly a widely applicable therapy. Studies have recently been done to help identify patients more likely to suffer stricture after photodynamic therapy. In addition, there has been evidence to suggest that the efficacy of photodynamic therapy also can be limited by genetic abnormalities in the mucosa. By combining knowledge of tissue biology, optical properties of the tissue, and dosimetry issues with ablation, photodynamic therapy can still have a potentially bright future.

Original languageEnglish (US)
Pages (from-to)1021-1025
Number of pages5
Issue number12
StatePublished - Dec 2008

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Photodynamic therapy for Barrett's esophagus: Does light still have a role?'. Together they form a unique fingerprint.

Cite this